Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Melanoma 53Carcinoma, Non-Small-Cell Lung 50Carcinoma, Renal Cell 32Neoplasms 29Neoplasm Metastasis 24Colorectal Neoplasms 21Carcinoma, Hepatocellular 21Squamous Cell Carcinoma of Head and Neck 18Stomach Neoplasms 16Triple Negative Breast Neoplasms 15Ovarian Neoplasms 14Small Cell Lung Carcinoma 11Pancreatic Neoplasms 11Lung Neoplasms 11Hodgkin Disease 11Carcinoma, Transitional Cell 10Advanced Cancer 9Sarcoma 8Recurrence 8Head and Neck Neoplasms 8Solid Tumor 7Prostatic Neoplasms 7Lymphoma, Non-Hodgkin 7Endometrial Neoplasms 7Uterine Cervical Neoplasms 6Urinary Bladder Neoplasms 6Carcinoma, Merkel Cell 6Breast Neoplasms 6Mesothelioma 5Glioblastoma 5

Interventions

pembrolizumab 1epacadostat 1copanlisib 1Nivolumab 1Fulvestrant 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Spinocerebellar Degenerations × Nivolumab × Clear all
NCT03711058 2025-09-16

Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 1/2 Completed
48 enrolled 16 charts
Gastrointestinal

Colonic Neoplasms, Neoplasm Metastasis, Spinocerebellar Degenerations

Data powered by HemOnc (CC BY 4.0) Colophon âš¡